Inicio>>Signaling Pathways>> PROTAC>> Ligand for E3 Ligase>>Lenalidomide-OH

Lenalidomide-OH

Catalog No.GC60223

Lenalidomida-OH es un anÁlogo del ligando de cereblon (CRBN) Lenalidomida para la ligasa de ubiquitina E3, y se utiliza en el reclutamiento de la proteÍna CRBN. La lenalidomida-OH se puede conectar al ligando de la proteÍna mediante un conector para formar PROTAC, como el degradador PROTAC BTK SJF620.

Products are for research use only. Not for human use. We do not sell to patients.

Lenalidomide-OH Chemical Structure

Cas No.: 1416990-08-3

Tamaño Precio Disponibilidad Cantidad
100mg
122,00 $
Disponible
500mg
365,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Lenalidomide-OH is an analog of cereblon (CRBN) ligand Lenalidomide for E3 ubiquitin ligase, and is used in the recruitment of CRBN protein. Lenalidomide-OH can be connected to the ligand for protein by a linker to form PROTACs, such as the PROTAC BTK degrader SJF620 [1].

Lenalidomide-OH can be connected to the ligand for protein by a linker to form PROTACs. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins[1].

[1]. Jaime-Figueroa S, et al. Design, synthesis and biological evaluation of Proteolysis Targeting Chimeras (PROTACs) as a BTK degraders with improved pharmacokinetic properties. 2020 Feb 1;30(3):126877.

Reseñas

Review for Lenalidomide-OH

Average Rating: 5 ★★★★★ (Based on Reviews and 38 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Lenalidomide-OH

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.